209 related articles for article (PubMed ID: 12892252)
1. Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis.
Skoumal M; Kolarz G; Klingler A
Scand J Rheumatol; 2003; 32(3):156-61. PubMed ID: 12892252
[TBL] [Abstract][Full Text] [Related]
2. [Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis].
Marti C; Neidhart M; Gerber T; Hauser N; Michel BA; Häuselmann HJ
Z Rheumatol; 1999 Apr; 58(2):79-87. PubMed ID: 10408068
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment.
Skoumal M; Haberhauer G; Feyertag J; Kittl EM; Bauer K; Dunky A
Rheumatol Int; 2006 Sep; 26(11):1001-4. PubMed ID: 16485108
[TBL] [Abstract][Full Text] [Related]
4. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis.
Wisłowska M; Jabłońska B
Clin Rheumatol; 2005 Jun; 24(3):278-84. PubMed ID: 15940561
[TBL] [Abstract][Full Text] [Related]
5. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis.
Morozzi G; Fabbroni M; Bellisai F; Cucini S; Simpatico A; Galeazzi M
Clin Rheumatol; 2007 Aug; 26(8):1335-8. PubMed ID: 17285224
[TBL] [Abstract][Full Text] [Related]
6. Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment.
Happonen KE; Saxne T; Geborek P; Andersson M; Bengtsson AA; Hesselstrand R; Heinegård D; Blom AM
Arthritis Res Ther; 2012 Jan; 14(1):R15. PubMed ID: 22264230
[TBL] [Abstract][Full Text] [Related]
7. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study.
Roux-Lombard P; Eberhardt K; Saxne T; Dayer JM; Wollheim FA
Rheumatology (Oxford); 2001 May; 40(5):544-51. PubMed ID: 11371663
[TBL] [Abstract][Full Text] [Related]
8. Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis--data from the RAPIT study.
de Jong Z; Munneke M; Vilim V; Zwinderman AH; Kroon HM; Ronday HK; Lems WF; Dijkmans BA; Breedveld FC; Vliet Vlieland TP; Hazes JM; Degroot J
Rheumatology (Oxford); 2008 Jun; 47(6):868-71. PubMed ID: 18400837
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy.
Niki Y; Takeuchi T; Nakayama M; Nagasawa H; Kurasawa T; Yamada H; Toyama Y; Miyamoto T
PLoS One; 2012; 7(5):e37447. PubMed ID: 22629396
[TBL] [Abstract][Full Text] [Related]
10. Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis.
Andersson ML; Svensson B; Petersson IF; Hafström I; Albertsson K; Forslind K; Heinegård D; Saxne T
BMC Musculoskelet Disord; 2013 Aug; 14():229. PubMed ID: 23915292
[TBL] [Abstract][Full Text] [Related]
11. [Evidence of cartilaginous benefit of treatment with infliximab in rheumatoid arthritis using measurement of serum COMP].
Yamamoto M; Takahashi H; Ohara M; Suzuki C; Naishiro Y; Yamamoto H; Shinomura Y; Imai K
Nihon Rinsho Meneki Gakkai Kaishi; 2007 Feb; 30(1):41-7. PubMed ID: 17332704
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis.
Kullich WC; Mur E; Aglas F; Niksic F; Czerwenka C
Clin Exp Rheumatol; 2006; 24(2):155-60. PubMed ID: 16762150
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.
Young-Min S; Cawston T; Marshall N; Coady D; Christgau S; Saxne T; Robins S; Griffiths I
Arthritis Rheum; 2007 Oct; 56(10):3236-47. PubMed ID: 17907159
[TBL] [Abstract][Full Text] [Related]
14. Cartilage Oligomeric Matrix Protein (COMP) in systemic sclerosis (SSc): role in disease severity and subclinical rheumatoid arthritis overlap.
Gheita TA; Hussein H
Joint Bone Spine; 2012 Jan; 79(1):51-6. PubMed ID: 21497537
[TBL] [Abstract][Full Text] [Related]
15. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.
Kawashiri SY; Kawakami A; Ueki Y; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Origuchi T; Ida H; Eguchi K
Joint Bone Spine; 2010 Oct; 77(5):418-20. PubMed ID: 20864374
[TBL] [Abstract][Full Text] [Related]
16. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression.
Syversen SW; Goll GL; van der Heijde D; Landewé R; Gaarder PI; Odegård S; Haavardsholm EA; Kvien TK
J Rheumatol; 2009 Feb; 36(2):266-72. PubMed ID: 19132792
[TBL] [Abstract][Full Text] [Related]
17. Cartilage oligomeric matrix protein in serum in systemic lupus erythematosus and knee osteoarthritis. Preliminary communication.
Wisłowska M; Jabłońska B
Rheumatol Int; 2005 Jun; 25(5):373-8. PubMed ID: 15739097
[TBL] [Abstract][Full Text] [Related]
18. HLA DRB1* typing and cartilage oligomeric matrix protein (COMP) as predictors of joint destruction in recent-onset rheumatoid arthritis.
Wollheim FA; Eberhardt KB; Johnson U; Saxne T
Br J Rheumatol; 1997 Aug; 36(8):847-9. PubMed ID: 9291852
[TBL] [Abstract][Full Text] [Related]
19. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation.
Neidhart M; Hauser N; Paulsson M; DiCesare PE; Michel BA; Häuselmann HJ
Br J Rheumatol; 1997 Nov; 36(11):1151-60. PubMed ID: 9402858
[TBL] [Abstract][Full Text] [Related]
20. Cartilage oligomeric matrix protein associates differentially with erosions and synovitis and has a different temporal course in cyclic citrullinated peptide antibody (anti-CCP)-positive versus anti-CCP-negative early rheumatoid arthritis.
Christensen AF; Lindegaard H; Hørslev-Petersen K; Hetland ML; Ejbjerg B; Stengaard-Pedersen K; Jacobsen S; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Tarp U; Pødenphant J; Østergaard M; Junker P
J Rheumatol; 2011 Aug; 38(8):1563-8. PubMed ID: 21572145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
